Cannapharmarx Inc (CPMD)
0.01
0.00 (0.00%)
USD |
OTCM |
May 03, 16:00
Cannapharmarx Enterprise Value: 16.69M for May 3, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 03, 2024 | 16.69M |
| May 02, 2024 | 16.69M |
| May 01, 2024 | 16.69M |
| April 30, 2024 | 16.69M |
| April 29, 2024 | 16.69M |
| April 26, 2024 | 16.69M |
| April 25, 2024 | 16.69M |
| April 24, 2024 | 16.69M |
| April 23, 2024 | 16.69M |
| April 22, 2024 | 16.69M |
| April 19, 2024 | 16.69M |
| April 18, 2024 | 16.69M |
| April 17, 2024 | 16.69M |
| April 16, 2024 | 18.21M |
| April 15, 2024 | 18.38M |
| April 12, 2024 | 18.04M |
| April 11, 2024 | 18.54M |
| April 10, 2024 | 18.54M |
| April 09, 2024 | 18.07M |
| April 08, 2024 | 19.22M |
| April 05, 2024 | 19.05M |
| April 04, 2024 | 18.04M |
| April 03, 2024 | 18.71M |
| April 02, 2024 | 19.10M |
| April 01, 2024 | 19.56M |
| Date | Value |
|---|---|
| March 28, 2024 | 18.31M |
| March 27, 2024 | 19.29M |
| March 26, 2024 | 18.88M |
| March 25, 2024 | 19.69M |
| March 22, 2024 | 19.39M |
| March 21, 2024 | 19.05M |
| March 20, 2024 | 18.07M |
| March 19, 2024 | 18.44M |
| March 18, 2024 | 17.36M |
| March 15, 2024 | 17.53M |
| March 14, 2024 | 18.38M |
| March 13, 2024 | 18.54M |
| March 12, 2024 | 18.38M |
| March 11, 2024 | 18.63M |
| March 08, 2024 | 19.90M |
| March 07, 2024 | 20.06M |
| March 06, 2024 | 19.39M |
| March 05, 2024 | 18.38M |
| March 04, 2024 | 17.70M |
| March 01, 2024 | 16.69M |
| February 29, 2024 | 17.02M |
| February 28, 2024 | 17.02M |
| February 27, 2024 | 16.69M |
| February 26, 2024 | 16.69M |
| February 23, 2024 | 16.31M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
10.55M
Minimum
Dec 30 2021
110.13M
Maximum
Aug 14 2020
29.02M
Average
15.08M
Median
Enterprise Value Benchmarks
| Acasti Pharma Inc | 2.708M |
| Aurinia Pharmaceuticals Inc | 378.91M |
| Edesa Biotech Inc | 10.43M |
| Lexaria Bioscience Corp | 35.17M |
| Xenon Pharmaceuticals Inc | 2.663B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -0.5644M |
| Total Expenses (Quarterly) | 0.6675M |
| EPS Diluted (Quarterly) | -0.0019 |
| Earnings Yield | -367.4% |